Condensed Consolidated Statements of Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common stock	Treasury Stock, Common	Additional paid-in capital	Retained earnings	Accumulated other comprehensive loss	Noncontrolling interest
Beginning balance at Dec. 31, 2021	$ 15,436	$ 18	$ (3,143)	$ 18,305	$ 3,127	$ (2,899)	$ 28
Beginning balance (in shares) at Dec. 31, 2021		1,768
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	5,414	$ 0	0	0	5,414	0	0
Other comprehensive income (loss), net of tax	(297)	0	0	0	0	(297)	0
Dividends declared	(5,025)	0	0	0	(5,025)	0	0
Purchases of treasury stock	(1,479)	$ 0	(1,479)	0	0	0	0
Purchases of treasury stock (in shares)		(10)
Stock-based compensation plans and other	632	$ 0	31	601	0	0	0
Stock-based compensation plans and other (in shares)		10
Change in noncontrolling interest	7	$ 0	0	0	0	0	7
Ending balance at Jun. 30, 2022	14,688	$ 18	(4,591)	18,906	3,516	(3,196)	35
Ending balance (in shares) at Jun. 30, 2022		1,768
Beginning balance at Mar. 31, 2022	16,314	$ 18	(4,585)	18,731	5,103	(2,984)	31
Beginning balance (in shares) at Mar. 31, 2022		1,767
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	924	$ 0	0	0	924	0	0
Other comprehensive income (loss), net of tax	(212)	0	0	0	0	(212)	0
Dividends declared	(2,511)	0	0	0	(2,511)	0	0
Purchases of treasury stock	(9)	$ 0	(9)	0	0	0	0
Purchases of treasury stock (in shares)		0
Stock-based compensation plans and other	178	$ 0	3	175	0	0	0
Stock-based compensation plans and other (in shares)		1
Change in noncontrolling interest	4	$ 0	0	0	0	0	4
Ending balance at Jun. 30, 2022	14,688	$ 18	(4,591)	18,906	3,516	(3,196)	35
Ending balance (in shares) at Jun. 30, 2022		1,768
Beginning balance at Dec. 31, 2022	17,287	$ 18	(4,594)	19,245	4,784	(2,199)	33
Beginning balance (in shares) at Dec. 31, 2022		1,769
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	2,263	$ 0	0	0	2,263	0	0
Other comprehensive income (loss), net of tax	(53)	0	0	0	0	(53)	0
Dividends declared	(5,258)	0	0	0	(5,258)	0	0
Purchases of treasury stock	(1,965)	$ 0	(1,965)	0	0	0	0
Purchases of treasury stock (in shares)		(12)
Stock-based compensation plans and other	625	$ 0	31	594	0	0	0
Stock-based compensation plans and other (in shares)		8
Change in noncontrolling interest	(1)	$ 0	0	0	0	0	(1)
Ending balance at Jun. 30, 2023	12,898	$ 18	(6,528)	19,839	1,789	(2,252)	32
Ending balance (in shares) at Jun. 30, 2023		1,765
Beginning balance at Mar. 31, 2023	13,303	$ 18	(6,524)	19,619	2,393	(2,232)	29
Beginning balance (in shares) at Mar. 31, 2023		1,764
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	2,024	$ 0	0	0	2,024	0	0
Other comprehensive income (loss), net of tax	(20)	0	0	0	0	(20)	0
Dividends declared	(2,628)	0	0	0	(2,628)	0	0
Purchases of treasury stock	(10)	$ 0	(10)	0	0	0	0
Purchases of treasury stock (in shares)		0
Stock-based compensation plans and other	226	$ 0	6	220	0	0	0
Stock-based compensation plans and other (in shares)		1
Change in noncontrolling interest	3	$ 0	0	0	0	0	3
Ending balance at Jun. 30, 2023	$ 12,898	$ 18	$ (6,528)	$ 19,839	$ 1,789	$ (2,252)	$ 32
Ending balance (in shares) at Jun. 30, 2023		1,765